Literature DB >> 19269757

Thymoma, immunodeficiency, and herpes simplex virus infections.

M Méan1, M D Schaller, S Asner, P Meylan, J-L Pagani, P Tarr, P Eggimann.   

Abstract

Hypogammaglobulinemia develops in 3 to 6% of patients with thymoma and this association is commonly referred to as thymoma with immunodeficiency (formerly Good syndrome). Recurrent infections with encapsulated bacteria and opportunistic infections associated with disorders of both humoral and cell mediated immunity frequently occur in this rare primary, adult-onset immunodeficiency. We report a case of thymoma with immunodeficiency complicated by disseminated herpes simplex virus (HSV) infection and review five additional cases of HSV-related infections reported since 1966 in patients presenting with thymoma with immunodeficiency. Patients presented with epiglottitis, keratitis, recurrent genital herpes, ulcerative dermatitis, and acute hepatitis. Four of the six cases had a fatal outcome, two of which were directly attributable to HSV infection. Since the risk of invasive opportunistic infections is high and the presentation atypical, lymphocyte count and total serum immunoglobulin should be measured regularly in all patients presenting with thymoma with immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269757     DOI: 10.1016/j.medmal.2009.01.008

Source DB:  PubMed          Journal:  Med Mal Infect        ISSN: 0399-077X            Impact factor:   2.152


  3 in total

Review 1.  Good's syndrome remains a mystery after 55 years: A systematic review of the scientific evidence.

Authors:  Theodoros Kelesidis; Otto Yang
Journal:  Clin Immunol       Date:  2010-02-10       Impact factor: 3.969

2.  Deficit of Anterior Pituitary Function and Variable Immune Deficiency Syndrome: A Novel Mutation.

Authors:  Pavadee Poowuttikul; Eric McGrath; Deepak Kamat
Journal:  Glob Pediatr Health       Date:  2017-01-27

Review 3.  Viral infection in thymoma and thymic tumors with autoimmune diseases.

Authors:  Rui Chang; Shuning Duan; Shicong Li; Peng Zhang
Journal:  Thorac Cancer       Date:  2021-09-17       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.